Insmed Incorporated (INSM)
-NasdaqCM 10.90 
0.34(3.22%) May 17, 4:00PM EDT|After Hours
:
10.99 0.09 (0.83%) May 17, 4:33PM EDT
| Prev Close: | 10.56 |
|---|
| Open: | 10.59 |
|---|
| Bid: | 8.87 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 14.25 |
|---|
| Beta: | 0.67 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 10.18 - 10.97 |
|---|
| 52wk Range: | 2.69 - 11.25 |
|---|
| Volume: | 440,262 |
|---|
| Avg Vol (3m): | 223,473 |
|---|
| Market Cap: | 344.12M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.71 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Insmed rises as analyst forecasts gains for stockAP(Wed, May 15)
- 2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Playat Seeking Alpha(Wed, May 15)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 14)
- Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmedat Seeking Alpha(Tue, May 14)
- Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in EuropeMarketwired(Tue, May 14)
- Insmed to Present at the UBS Global Healthcare ConferenceMarketwired(Mon, May 13)
- INSMED INC FinancialsEDGAR Online Financials(Fri, May 10)
- Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care ConferenceMarketwired(Fri, May 10)
- Insmed's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Insmed Incorporated Earnings Call scheduled for 8:30 am ET todayCCBN(Tue, May 7)
- Insmed Reports First Quarter Financial ResultsMarketwired(Tue, May 7)
- Q1 2013 Insmed Incorporated Earnings Release - Before Market OpenCCBN(Tue, May 7)
- INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- INSMED INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Biotech Stock Value Fundamentally Based on Individual Drug Development and the Competing Landscape: Expert Analyst Boris Peaker Discusses His Coverage of the Biotechnology Sector with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.71 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.36 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases.
View More